Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 5, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 29, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 6, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record95412 flagged findings
Reported transactions (Form 4)80since Mar 2, 2026 · and 7 other holdings
Corporate events (8-K)30since Dec 14, 2020
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-08-06share offering or dilution eventfreshOpen filing ↗“…in the expected timeframe or at all, and our business, financial condition, and results of operations may be materially adversely…”
+1 more passage from the same document
- “…in the consolidated complaint on November 24, 2025, the plaintiff’s response to which will be filed after resolution of certain…”
- 2026-08-06Department of Justice inquiryfreshOpen filing ↗“…advisory opinion can be requested from the Department of Health and Human Services’ Office of Inspector General, or OIG, regarding…”
+1 more passage from the same document
- “…and government fines. We, and any of our collaborators, must comply with requirements concerning advertising and promotion for any…”
- 2026-08-06reverse splitfreshOpen filing ↗“…November 2012, they provided the Company $ 0.1 million and that they advanced and paid on behalf of the Company an additional $ 0.2…”
+1 more passage from the same document
- “…June and November 2012, they provided the Company $ 0.1 million and that they advanced and paid on behalf of the Company an…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 954)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 5, 268-K ↗Current report · Other events
- Oct 2, 26Form 4 ↗Insider transaction
- Oct 2, 26Form 3 ↗Insider transaction
- Sep 29, 268-K ↗Current report · Other events
Insider transaction · 8 Form 4 filingsshow all 8hide
- Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 5.5% · event on Jun 30, 26
- Aug 6, 268-K ↗Current report · Other events
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 28, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 7.5% · event on Jun 30, 26 · amendment
- Jul 2, 268-K ↗Current report · Other events
- Jun 18, 26S-3ASR ↗Securities offering
- Jun 10, 268-K ↗Current report · Shareholder vote results · Other events
954 filings on record, the oldest from Mar 7, 08.
Listing the 25 most recent filings of the 954 on record.
17670
- Mar 20, 26A senior executive left or was appointed8-K 5.02 ↗
- Aug 22, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
4 senior executive changes2025show all 4hide
- Aug 7, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jul 15, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jul 3, 25A senior executive left or was appointed8-K 5.02 ↗
- Jun 13, 25A senior executive left or was appointed8-K 5.02 ↗
- Nov 21, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Mar 29, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
3 material agreements entered2023 – 2024show all 3hide
- Feb 20, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jul 11, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jun 16, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- May 18, 23Completed an acquisition or disposal+1 more in the same filing8-K 2.01 ↗
- Apr 24, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 23, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Nov 18, 22Entered a material agreement+2 more in the same filing8-K 1.01 ↗
5 senior executive changes2021 – 2022show all 5hide
- Jun 13, 22A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Jan 19, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 23, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 14, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 19, 21A senior executive left or was appointed8-K 5.02 ↗
- May 6, 21Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 older filings not shown · The record reaches back to Aug 6, 09.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Mar 6, 12Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
The full record holds 1 stress filing.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.7.5%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- The Vanguard Group7.5%Jun 30, 25SCHEDULE 13G/A ↗
- STATE STREET CORPORATION5.5%Jun 30, 26SCHEDULE 13G ↗2 earlier filings
- Perceptive Advisors LLC3.8%Mar 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
No purchases or sales are on record in this stretch; only other transactions (compensation, withholding, exercises or gifts).
Stock compensation, tax and giftsshow the 40 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 8, 26Compensationamount n/aRaj K. PuriChief Regulatory Officer↗
- Sep 8, 26Tax$39KRaj K. PuriChief Regulatory Officer↗
- Sep 8, 26Compensationamount n/aIGOR BILINSKYChief Operating Officer↗
- Sep 8, 26Tax$35KIGOR BILINSKYChief Operating Officer↗
- Sep 8, 26Compensationamount n/aFrederick G VogtInterim CEO & General Counsel↗
- Sep 8, 26Tax$58KFrederick G VogtInterim CEO & General Counsel↗
- Sep 1, 26Compensationamount n/aIGOR BILINSKYChief Operating Officer↗
- Sep 1, 26Tax$37KIGOR BILINSKYChief Operating Officer↗
- Sep 1, 26Compensationamount n/aRaj K. PuriChief Regulatory Officer↗
- Sep 1, 26Tax$21KRaj K. PuriChief Regulatory Officer↗
- Sep 1, 26Compensationamount n/aFrederick G VogtInterim CEO & General Counsel↗
- Sep 1, 26Tax$147KFrederick G VogtInterim CEO & General Counsel↗
- Aug 10, 26Compensationamount n/aDaniel Gordon KirbyChief Commercial Officer↗
- Aug 10, 26Tax$16KDaniel Gordon KirbyChief Commercial Officer↗
- Aug 6, 26Compensationamount n/aCorleen M. RocheChief Financial Officer↗
- Aug 6, 26Tax$132KCorleen M. RocheChief Financial Officer↗
- Jun 5, 26Compensationamount n/aIGOR BILINSKYChief Operating Officer↗
- Jun 5, 26Tax$17KIGOR BILINSKYChief Operating Officer↗
- Jun 5, 26Compensationamount n/aRaj K. PuriChief Regulatory Officer↗
- Jun 5, 26Tax$16KRaj K. PuriChief Regulatory Officer↗
- Jun 5, 26Compensationamount n/aFINCKENSTEIN FRIEDRICH GRAFChief Medical Officer↗
- Jun 5, 26Tax$17KFINCKENSTEIN FRIEDRICH GRAFChief Medical Officer↗
- Jun 5, 26Compensationamount n/aFrederick G VogtInterim CEO & General Counsel↗
- Jun 5, 26Tax$28KFrederick G VogtInterim CEO & General Counsel↗
- Jun 1, 26Compensationamount n/aIGOR BILINSKYChief Operating Officer↗
- Jun 1, 26Tax$18KIGOR BILINSKYChief Operating Officer↗
- Jun 1, 26Compensationamount n/aFINCKENSTEIN FRIEDRICH GRAFChief Medical Officer↗
- Jun 1, 26Tax$18KFINCKENSTEIN FRIEDRICH GRAFChief Medical Officer↗
- Jun 1, 26Compensationamount n/aRaj K. PuriChief Regulatory Officer↗
- Jun 1, 26Tax$10KRaj K. PuriChief Regulatory Officer↗
- Jun 1, 26Compensationamount n/aFrederick G VogtInterim CEO & General Counsel↗
- Jun 1, 26Tax$70KFrederick G VogtInterim CEO & General Counsel↗
- May 11, 26Compensationamount n/aDaniel Gordon KirbyChief Commercial Officer↗
- May 11, 26Tax$9KDaniel Gordon KirbyChief Commercial Officer↗
- Mar 5, 26Compensationamount n/aIGOR BILINSKYChief Operating Officer↗
- Mar 5, 26Tax$76KIGOR BILINSKYChief Operating Officer↗
- Mar 5, 26Compensationamount n/aRaj K. PuriChief Regulatory Officer↗
- Mar 5, 26Tax$84KRaj K. PuriChief Regulatory Officer↗
- Mar 5, 26Compensationamount n/aFINCKENSTEIN FRIEDRICH GRAFChief Medical Officer↗
- Mar 5, 26Tax$76KFINCKENSTEIN FRIEDRICH GRAFChief Medical Officer↗
The full record holds 202 transactions and goes back to Jan 3, 23.
Its sector and its market
Iovance Biotherapeutics, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Iovance Biotherapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Iovance Biotherapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 954 documents on file, from Mar 7, 2008 to Oct 5, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.